KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $1.6 billion.

  • Bristol Myers Squibb's Free Cash Flow fell 6050.23% to $1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.8 billion, marking a year-over-year decrease of 786.83%. This contributed to the annual value of $12.8 billion for FY2025, which is 786.83% down from last year.
  • Latest data reveals that Bristol Myers Squibb reported Free Cash Flow of $1.6 billion as of Q4 2025, which was down 6050.23% from $6.0 billion recorded in Q3 2025.
  • Over the past 5 years, Bristol Myers Squibb's Free Cash Flow peaked at $6.0 billion during Q3 2025, and registered a low of $1.6 billion during Q4 2025.
  • Moreover, its 5-year median value for Free Cash Flow was $3.5 billion (2022), whereas its average is $3.3 billion.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 13632.92% in 2021, then crashed by 6050.23% in 2025.
  • Over the past 5 years, Bristol Myers Squibb's Free Cash Flow (Quarter) stood at $3.7 billion in 2021, then dropped by 20.79% to $3.0 billion in 2022, then soared by 32.5% to $3.9 billion in 2023, then grew by 3.54% to $4.1 billion in 2024, then tumbled by 60.5% to $1.6 billion in 2025.
  • Its Free Cash Flow stands at $1.6 billion for Q4 2025, versus $6.0 billion for Q3 2025 and $3.6 billion for Q2 2025.